

ECONMED EUROPE

**IRESSA® (GEFITYNIB) W LECZENIU
NIEDROBNOKOMÓRKOWEGO RAKA
PŁUCA PO NIEPOWODZENIU
WCZEŚNIEJSZEJ LINII
CHEMIOTERAPII**

ZAŁĄCZNIKI

**ANALIZA EKONOMICZNA
I WPLYWU NA SYSTEM OCHRONY ZDROWIA**



KRAKÓW 2013

**OPRACOWALI:
BEATA LISIECKA
MICHAŁ SEWERYN
RAFAŁ NIŻANKOWSKI
MAGDALENA KOPERNY
AGNIESZKA KARGUL**



WWW.ECONMED.EU

Spis treści

Załącznik 1	3
Załącznik 2	7
Załącznik 3	8
Załącznik 4	14
Załącznik 5	14
Załącznik 6	17
Załącznik 7	21
Załącznik 8	29
Piśmiennictwo	30

Załącznik 1

Iressa® (gefitynib) w leczeniu niedrobnokomórkowego raka płuca po niepowodzeniu wcześniejszej linii chemioterapii. Analiza ekonomiczna i wpływu na system ochrony zdrowia. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XXXXX	X	XXXXXXXX XX [XXXX.]	XX (XXXXXX)	X
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]


XXXXX	X	XXXXXXXXXXXXXXXXXXXXX	XXXXXXXXXXXX	X
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

XXXXXXXXXXXXXXX	XXX	XXXXXXXXXX	XXXXXXXXXXXX
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]



Załącznik 2

Iressa® (gefitynib) w leczeniu niedrobnokomórkowego raka płuca po niepowodzeniu wcześniejszej linii chemioterapii. Analiza ekonomiczna i wpływu na system ochrony zdrowia. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XXXXX	X	X (X)	XX (XXX XX)	X
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Załącznik 3

Iressa® (gefitynib) w leczeniu niedrobnokomórkowego raka płuca po niepowodzeniu wcześniejszej linii chemioterapii. Analiza ekonomiczna i wpływu na system ochrony zdrowia. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XX	XXXXXXXXXX (XXXXXXXXXX)
----	-------------------------

■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]
■	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XXXX XXXXXXXXXXXX	XXXXXX XXXX (XXXXXXXX XX)	XXXXXX XXXX (XXXXXXXX XXX)	XXXXXXXX XXXX (XXXXXXXX XX)	XXXXXXXXXX XXXX (XX-XX)	XXXXXX XXXX (XXXXXXXX XX)
[REDACTED]	■	■	■	■	■
[REDACTED]	■	■	■	■	■
[REDACTED] [REDACTED]	■	■		■	
[REDACTED] [REDACTED]	■	■		■	
[REDACTED]	■	■	■	■	

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XXXXXXXXXX XXXXXXXXXXXXXXX	XXXXXXXXXX XXXXXXXXXXXXXXXXXXXX	XXXXXXXXXXXX XXXXXXXXXXXXXXX	XXXXXXXXXX XXXXXXXXXXXXXXXXXXXX
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

Załącznik 4

Iressa® (gefitynib) w leczeniu niedrobnokomórkowego raka płuca po niepowodzeniu wcześniejszej linii chemioterapii. Analiza ekonomiczna i wpływu na system ochrony zdrowia. [REDACTED]

[REDACTED]

[REDACTED]

Załącznik 5

Iressa® (gefitynib) w leczeniu niedrobnokomórkowego raka płuca po niepowodzeniu wcześniejszej linii chemioterapii. Analiza ekonomiczna i wpływu na system ochrony zdrowia. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[REDACTED]

XXXXXXXXXX XXXXXXXXXXXXXX XX. X/X XXXXX XXXXXXXXXXXXXX XXXXXXXX XXXXXXXX [XX]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Załącznik 6

Iressa® (gefitynib) w leczeniu niedrobnokomórkowego raka płuca po niepowodzeniu wcześniejszej linii chemioterapii. Analiza ekonomiczna i wpływu na system ochrony zdrowia. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	xx	[REDACTED]	xx/xxx	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XXXXXXXXXX XXXX XXXXXXXXXXXXXXXX	XXXXXXX XXXXXXXXX	XXXXXXX
----------------------------------	-------------------	---------

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
T	[REDACTED]	[REDACTED]	[REDACTED]
T	[REDACTED]	[REDACTED]	[REDACTED]
	[REDACTED]	[REDACTED]	[REDACTED]

XXXXXXXXXX XXXX XXXXXXXXXXXXXXXX	XXXXXXX XXXXXXXXXX	XXXXXXX
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

	XXXXXXXX XXXXXXXX XX XXXXXXXX	XXXXX XXXXXXXXXXXX [XX]	XXXXXX XXXXXXXXXXXX XXXXXXXXXXXX [XX/XXXXXXXX]	XXXXXXXX XXXXX XX XXXXXXX XXXXXXXX
--	-------------------------------------	-------------------------------	---	--

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Załącznik 7

Iressa® (gefitynib) w leczeniu niedrobnokomórkowego raka płuca po niepowodzeniu wcześniejszej linii chemioterapii. Analiza ekonomiczna i wpływu na system ochrony zdrowia. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XXX	XXXXXXXX	XXXXXXXX	XXXXXXXX X XXXXX (XXX)	XXXXX
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]		[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Redacted text]

[Redacted text]

XXXXXXXXXXXXXXXXXXXX	XXXXXXXXXXXXXXXXXXXX	XXXXXX
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]

[Redacted text]

[REDACTED]

[REDACTED]

[REDACTED]

XXXXXXXXXX	XXXXXXX	XXXXXXX
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

XX	XXXXXXXXXX (XXXXXXXXXX)	XXXXXX XXXXXXXXXX
■	[REDACTED]	■
■	[REDACTED]	■
■	■	■
■	[REDACTED]	■
■	[REDACTED]	■
■	[REDACTED]	■
■	[REDACTED]	■
■	[REDACTED]	■

[Redacted text block]

XXXXXXXXXXXXXXXXXXXX XXXXXXXX	XXXXXXXXXX XXXXXXXX XXXXXXXXXXXXXXXXXX*	XXXXXX
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]	XXXXXXXX	XXXXXXXX XXXXXXXXXXXX	XXXXXXXX XXXXXXXXXXXX	XXXXXXXX XXXXXXXXXXXX
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Załącznik 8

[REDACTED]

[REDACTED]	[REDACTED]
I	[REDACTED]
II	[REDACTED]
III	[REDACTED]
IV	[REDACTED]
V	[REDACTED]
VI	[REDACTED]
VII	[REDACTED]

■	
---	--

Piśmiennictwo

[REDACTED]

[REDACTED]

Araújo 2008

Araújo A, Parente B, Sotto-Mayor R, Teixeira E, Almodôvar T, Barata F, Queiroga. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol. 2008 Nov-Dec;14(6):803-27.

Batura-Gabryel 2008

Batura-Gabryel H. Sesja satelitarna. Rak płuca – koniec czy początek możliwości diagnostyczno-terapeutycznych. Rak płuca jako problem pulmonologiczny. Przew Lek 2008; 1: 11-14.

Bell 2005

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 1;23(31):8081-92.

Bolin 2008

Bolin K, Mörk AC, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy – cost-utility results from Sweden 2003. Respir Med. 2008; 102(5):699-710.

Bonomi 2004

Bonomi PD. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Nov;6(3):154-61.

Cappuzzo 2005

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97: 643-655.

Carlson 2008

Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory

- non-small cell lung cancer (NSCLC). Lung Cancer. 2008 Sep;61(3):405-15.
- Carlson 2009** Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer. Value Health 2009; 12(1): 20-27.
- Chan 2005** Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer – search and destroy. Eur J Cancer. 2006 Jan;42(1):17-23.
- Colice 1995** Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestri G. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest. 1995 Nov;108(5):1264-71.
- Cortes-Funes 2005** Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005;16: 1081-1086.
- Coskeran 2006b** Coskeran T, Denman A, Phillips P, Tornberg R. A cost-effectiveness analysis of radon protection methods in domestic properties: a comparative case study in Brixworth, Northamptonshire, UK. Journal of Environmental Radioactivity; Volume 91, Issues 1-2, 2006, Pages 73-89.
- Eberhard 2005** Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanoovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 1;23(25):5900-9.
- Feenstra 2005** Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Mölken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health. 2005 May-Jun;8(3):178-90.
- Ferguson 2003a** Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg. 2003 Dec;76(6):1782-8.
- Ferguson 2003b** Ferguson MK. Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J

- Thorac Cardiovasc Surg. 2003 Dec;126(6):1935-42.
- Gazdar 2009** Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene* 2009;28, S24-S31.
- Gołecky 2006** Gołecky M. Postępy w terapii celowanej niedrobnokomórkowego raka płuca. *Adv Clin Exp Med* 2006;15, 6, 1107–1112.
- Gould 2003** Gould MK, Sanders GD, Barnett PG, Rydzak CE, Maclean CC, McClellan MB, Owens DK. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. *Ann Intern Med.* 2003 May 6;138(9):724-35.
- Grunenwald 2005** Grunenwald DH. The role of surgery in non-small-cell lung cancers. *Annals of Oncology* 16 (Supplement 2): ii220–ii222, 2005.
- Hirsch 2006** Hirsch FR, Varella-Garcia M, Bunn PA Jr., Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B: Molecular predictors of outcome with gefitynib in a phase III placebo-controlled study in advanced non-smallcell lung cancer. *J Clin Oncol* 2006, 24:5034-5042.
- Hoogendoorn 2008** Hoogendoorn M, Welsing P, Rutten-van Mólken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. *Curr Med Res Opin.* 2008 Jan;24(1):51-61.
- Howard 2008** Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. *Pharmacoeconomics.* 2008;26(6):497-511.
- Jassem 2005** Jassem J, Drosik K, Dziadziuszko R, Kordek R, Kozielski J, Kowalski D, Krzakowski M, Niklifski J, Olszewski W, Orłowski T, Ramlau R, Roszkowski-Śliż K, Utracka-Hutka B, Wojtukiewicz M. Zalecenia dotyczące systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Konferencja okrągłego stołu. *Nowotwory. Journal of Oncology* 2005; 55(2): 160–166.
- Johansson 2005** Johansson PM, Tillgren PE, Guldbbrandsson KA, Lindholm LA. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. *Scand J Public Health.*

2005;33(5):343-52.

- John 2009** John T, Liu G, Tsao M-S. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. *Oncogene* 2009;28,S14-S23.
- Kalikaki 2009** Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulas V, Voutsina A. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. *Lung Cancer*. 2009 Oct 23.
- Kim 2008** Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. *Lancet*. 2008;372(9652):1809-1818.
- Kind 2005** Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states. *Pharmacoeconomics*. 2005;23(11):1143-53.
- Kotas 2001** Kotas M, Willner J, Flentje M. Sequential chemo-radiotherapy in non-small cell lung cancer. *Lung Cancer*. 2001 Sep;33 Suppl 1:S61-4.
- KRN 2009** Krajowy Rejestr Nowotworów. Raporty na podstawie centrum onkologii. Dostępne pod adresem: <http://85.128.14.124/krn/>. Data ostatniego dostępu: 21 grudnia 2009.
- Lalami 2006** Lalami Y, Paesmans M, Muanza F, Barette M, Plehiers B, Dubreucq L, Georgala A, Klastersky J. Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. *Ann Oncol*. 2006 Mar;17(3):507-14.
- Lamers 2007** Lamers LM, Uyl-de Groot CA, Buijt I. The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale. *Pharmacoeconomics*. 2007;25(7):591-603.
- Lang 2009** Lang K, Marciniak MD, Faries D, Stokes M, Buesching D, Earle C, Treat J, Morissette N, Thompson D. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell

lung cancer in the United States.

Lung Cancer 63 (2009) 264–270.

- Lewandowski 2003** Lewandowski T. Rak płuca. Nowa Medycyna – Onkologia VI (3/2003).
- Lievens 2005** Lievens Y, Kesteloot K, Van den Bogaert W. CHART in lung cancer: economic evaluation and incentives for implementation. Radiother Oncol. 2005 May;75(2):171-8.
- Lloyd 2005** Lloyd A, van Hanswijck de Jonge P, Doyle S, Walker M, Farina C: Development and elicitation of health state utilities in Metastatic Non Small cell lung cancer (NSCLC) in the UK. Poster presented at: The 27th Annual Meeting of the Society for Medical Decision Making 2005.
- Lynch 2004** Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129–2139.
- Mack 2009** Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR. EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Oct 30.
- Mahadevia 2003** Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003 Jan 15;289(3):313-22
- Manser 2005** Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer. 2005 May;48(2):171-85.
- Manser 2006** Manser RL, Wright G, Byrnes G, Hart D, Conron M, Carter R, McLachlan SA, Campbell DA. Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and inoperable lung cancer. Lung Cancer. 2006 Aug;53(2):217-29.
- Marchetti 2005** Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin

Oncol 2005;23: 857–865.

- Marciniak 2007** Marciniak M, Kołodziej J, Pawełczyk K. Chirurgiczne standardy leczenia raka płuca. Adv Clin Exp Med 2004;13, 6, 1079-1083.
- Massarelli 2007** Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 2007; 13(10):2890-2896.
- Movsas 1999** Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras E. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1143-9.
- Nafees 2008** Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008 Oct 21;6:84.
- NFZ 62/2009** Zarządzenie Nr 62/2009/DSOZ Funduszu Zdrowia z dnia 2 listopada 2009 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju ambulatoryjna opieka specjalistyczna.
- NFZ 66/2009** Zarządzenie Nr 66/2009/DGL Prezesa Narodowego Funduszu Zdrowia z dnia 3 listopada 2009 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju leczenie szpitalne w zakresie chemioterapii.
- NFZ 69/2009** Zarządzenie Nr 69/2009/DSOZ Prezesa Narodowego Funduszu Zdrowia z dnia 3 listopada 2009 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju: leczenie szpitalne.
- NICE 2005** National Institute for Clinical Excellence. The diagnosis and treatment of lung cancer. National cost-impact report. February 2005. www.nice.org.uk.
- NICE/TA162 2007** NICE. ERG report: Pemetrexed for the treatment of non-small-cell lung cancer. Liverpool: The National Institute for Health and Clinical Excellence; 2007.

- NICE/TA181 2007** NICE. ERG report: Pemetrexed for the first-line treatment of non-small-cell lung cancer. The National Institute for Health and Clinical Excellence; September 2009.
- Nomura 2007** Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007 Apr;4(4):e125.
- Orlewska 2009** Orlewska E. Erlotynib w leczeniu chorych z niedrobnokomórkowym rakiem płuca w Polsce – analiza wpływu na budżet. Farmakoekonomika 2009; 13 (1): 3-11.
- Paez 2004** Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4;304(5676):1497-500.
- Papatheofanis 2000** Papatheofanis FJ. Utility evaluations for Markov states of lung cancer for PET-based disease management. Q J Nucl Med. 2000 Jun;44(2):186-90.
- Payne 2008** Willmore-Payne C, Holden JA, Wittwer CT, Layfield LJ. The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer. J Biomol Tech. 2008 Jul;19(3):217-24.
- Pickard 2006** Pickard AS, Dobrez D, Cella D. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states [letter]. Pharmacoeconomics 2006; 24 (3): 293-4.
- Pickard 2007** Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007 Dec 21;5:70.
- Pinter 2008** Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, Kopper L, Schwab R, Petak I. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn. 2008 Mar;10(2):160-8.
- PUO 2009** Krzakowski M. i wsp. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. PUO 2009.

<http://www.onkologia.zalecenia.med.pl/>. Data ostatniego dostępu:
12.12.2009.

- Raab 1997** Raab SS, Hornberger J. The effect of a patient's risk-taking attitude on the cost effectiveness of testing strategies in the evaluation of pulmonary lesions. *Chest*. 1997 Jun;111(6):1583-90.
- Ramsey 2008** Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. *Am J Manag Care*. 2008 May;14(5):297-306.
- Riely 2008** Riely GJ. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. *Lung Cancer*. 2008 Jun;60 Suppl 2:S19-22.
- Rosell 2009** Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med*. 2009 Sep 3;361(10):958-67.
- Rosell 2009a** Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. *Curr Opin Oncol*. 2009 Nov 25.
- Rzyman 2008** Rzyman W. Rak płuca. *Forum medycyny rodzinnej*. 2008;2(6):407-419
- Sharma 2007** Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nature Reviews Cancer* 2007;7: 169-181.
- Shigematsu 2006** Shigematsu, H., and Gazdar, A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. *Int. J. Cancer*. 2006;118:257-262.
- Słowik-Gabryelska 2000** Słowik-Gabryelska A, Sokołowski J. Badania epidemiologiczne chorych na raka płuca leczonych w ciągu dziesięciu lat w wybranym rejonie województwa Kujawsko-Pomorskiego. *Onkol. Pol.* 2000, 3, 3: 129-135.

- Stigum 2003** Stigum H, Strand T, Magnus P. Should radon be reduced in homes? A cost-effect analysis. *Health Phys.* 2003 Feb;84(2):227-35.
- Stinchcombe 2006** Stinchcombe TE, Lee CB, Socinski MA. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. *Clin Lung Cancer* 2006 May;7 Suppl 4:S111-7.
- Tabberer 2006** Tabberer M, Stamuli E, Walker M, Summerhayes M, Lees M. Utilities associated with non-small cell lung cancer (NSCLC): a community study. *Value Health* 2006;9:A298.
- Takano 2008** Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. *J Clin Oncol.* 2008 Dec 1;26(34):5589-95.
- Tilden 2003** Tilden D, Aristides M, Stynes G, Orlewska E, Krzakowski M, Jassem J, Załuski J, Włodarczyk H. Analiza kosztów i efektów stosowania gemcytabiny w połączeniu z cisplatyną w porównaniu z winorelbiną w połączeniu z cisplatyną w leczeniu niedrobnokomórkowego raka płuca w Polsce: retrospektywna analiza ekonomiczna badań klinicznych. *Farmakoekonomika* 2003; 8 (3):3-23.
- Trippoli 2001** Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. *Pharmacoeconomics.* 2001;19(8):855-63.
- Tsao 2005** Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. *N Engl J Med* 2005;353(2):133–44.
- van den Hout 2006** van den Hout WB, Kramer GW, Noordijk EM, Leer JW. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. *J Natl Cancer Inst.* 2006 Dec 20;98(24):1786-94.
- Whynes 2008** Whynes DK. Could CT screening for lung cancer ever be cost effective in the United Kingdom? *Cost Eff Resour Alloc.* 2008 Feb 26;6:5.
- Zimmer 2009** Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, Merkelbach-Bruse S, Buettner R, Heukamp LC. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3

signaling. J Cancer Res Clin Oncol (2009) 135:723–730.